244 related articles for article (PubMed ID: 15584862)
1. Therapeutic potential of target of rapamycin inhibitors.
Easton JB; Houghton PJ
Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of mammalian target of rapamycin inhibitors.
Dancey JE
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1101-14. PubMed ID: 12512385
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus, the first mTOR inhibitor.
Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
[No Abstract] [Full Text] [Related]
4. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
5. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
7. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
8. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
10. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
11. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
12. Current development of mTOR inhibitors as anticancer agents.
Faivre S; Kroemer G; Raymond E
Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
[TBL] [Abstract][Full Text] [Related]
13. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD; Buckner JC; Sarkaria JN
Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Chaisuparat R; Hu J; Jham BC; Knight ZA; Shokat KM; Montaner S
Cancer Res; 2008 Oct; 68(20):8361-8. PubMed ID: 18922908
[TBL] [Abstract][Full Text] [Related]
17. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
[TBL] [Abstract][Full Text] [Related]
18. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin's resurrection: a new way to target the cancer cell cycle.
Garber K
J Natl Cancer Inst; 2001 Oct; 93(20):1517-9. PubMed ID: 11604470
[No Abstract] [Full Text] [Related]
20. Dissecting the role of mTOR: lessons from mTOR inhibitors.
Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
